Clinical Trials Logo

Clinical Trial Summary

The main aim is to check the long-term side effects of treatment with Brentuximab Vedotin and to see if that treatment improves symptoms of cluster of differentiation antigen 30 (CD30-Positive) Cutaneous T-Cell Lymphoma in Chinese adults. Participants will receive brentuximab vedotin through the vein on day 1 of each 21 day cycle up to maximum 16 cycles.


Clinical Trial Description

The drug being tested in this study is called brentuximab vedotin (SGN-35). Brentuximab vedotin is being tested to treat people who have CD30-positive cutaneous T-Cell lymphoma. The study will enroll approximately 10 patients. Participants will receive a single treatment i.e., brentuximab vedotin monotherapy: • Brentuximab vedotin 1.8 mg/kg Participants will be administered with brentuximab vedotin by intravenous (IV) infusion given for approximately 30 minutes on Day 1 of each 21-day cycle up to 16 cycles followed by the end of treatment (EOT) visit 30 days after receiving the final dose of study drug. Participants with progressive disease (PD) at any time during the study will be discontinued from study drug. This multi-center trial will be conducted in China. Participants will remain in this study for approximately 56 weeks. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05442554
Study type Interventional
Source Takeda
Contact
Status Active, not recruiting
Phase Phase 4
Start date July 20, 2023
Completion date September 30, 2024

See also
  Status Clinical Trial Phase
Completed NCT00959686 - Bendamustine in Patients With Refractory or Relapsed T-cell Lymphoma Phase 2
Active, not recruiting NCT04712864 - Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma Phase 1
Recruiting NCT05665530 - A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib in Participants With R/R Hematologic Malignancies Phase 1
Completed NCT01941680 - High Risk Adult T-cell Leukemia/Lymphoma (ATLL-HR) and Allogeneic Transplant
Recruiting NCT05075460 - Tucidinostat, Azacitidine Combined With CHOP Versus CHOP in Patients With Untreated Peripheral T-cell Lymphoma Phase 3
Completed NCT03734601 - Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation Phase 2
Completed NCT02017613 - Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in Hematological Malignancies Phase 1
Enrolling by invitation NCT01854112 - Helical Irradiation of Total Skin (HITS) for T Cell Lymphoma N/A
Completed NCT01553786 - Efficacy of a Treatment With CHOP and Lenalidomide in First Line in Angioimmunoblastic T-cell Lymphoma (AITL) Phase 2
Completed NCT00542919 - A Study for Patients With Non-Hodgkin's Lymphomas Phase 2
Recruiting NCT06131801 - Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Active, not recruiting NCT03952078 - A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma Phase 1
Not yet recruiting NCT05387226 - Intravenous Injection of Oncolytic Virus Injection (RT-01) in Patients With Relapsed or Refractory T-cell Lymphoma Phase 1
Completed NCT02424045 - Bendamustine, Carboplatin and Dexamethasone (BCD) for Refractory or Relapsed Peripheral T-cell Lymphoma Phase 2
Completed NCT01871675 - Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies Phase 1
Terminated NCT00893516 - CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell Lymphoma Phase 2
Completed NCT01902225 - Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma Phase 1
Recruiting NCT02086591 - A Phase II Study of Doxycycline in Relapsed NHL Phase 2
Recruiting NCT04264078 - Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic Malignancies Early Phase 1
Completed NCT00001582 - Investigation of the Human Immune Response in Normal Subjects and Patients With Disorders of the Immune System and Cancer